Oropharyngeal Cancer - Pipeline Review, H2 2016

Date: October 30, 2016
Pages: 144
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O602568CCECEN
Leaflet:

Download PDF Leaflet

Oropharyngeal Cancer - Pipeline Review, H2 2016
Oropharyngeal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer – Pipeline Review, H2 2016, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.

Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.Oropharyngeal Cancer.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Oropharyngeal Cancer Overview
Therapeutics Development
Pipeline Products for Oropharyngeal Cancer - Overview
Pipeline Products for Oropharyngeal Cancer - Comparative Analysis
Oropharyngeal Cancer - Therapeutics under Development by Companies
Oropharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes
Oropharyngeal Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Oropharyngeal Cancer - Products under Development by Companies
Oropharyngeal Cancer - Products under Investigation by Universities/Institutes
Oropharyngeal Cancer - Companies Involved in Therapeutics Development
Advaxis, Inc.
AstraZeneca Plc
Cell Medica Limited
Genticel S.A.
Immunovaccine Inc
ISA Pharmaceuticals B.V.
Kolltan Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
PNP Therapeutics, Inc.
Tessa Therapeutics Pte Ltd
VLPbio
Oropharyngeal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alpelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axalimogene filolisbac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMD-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPXE-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganetespib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gedeptin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HNVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISA-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KTN-3379 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nimotuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oropharyngeal Cancer - Dormant Projects
Oropharyngeal Cancer - Product Development Milestones
Featured News & Press Releases
Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage
Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform
Sep 14, 2015: FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer
Jun 09, 2015: U.S. FDA approves IND application for TT12 HP-VST to begin Phase I trial involving Adoptive T cell therapy on Oropharyngeal Cancer and Cervical Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Oropharyngeal Cancer, H2 2016
Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Oropharyngeal Cancer - Pipeline by Advaxis, Inc., H2 2016
Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H2 2016
Oropharyngeal Cancer - Pipeline by Cell Medica Limited, H2 2016
Oropharyngeal Cancer - Pipeline by Genticel S.A., H2 2016
Oropharyngeal Cancer - Pipeline by Immunovaccine Inc, H2 2016
Oropharyngeal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2016
Oropharyngeal Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
Oropharyngeal Cancer - Pipeline by Merck & Co., Inc., H2 2016
Oropharyngeal Cancer - Pipeline by Novartis AG, H2 2016
Oropharyngeal Cancer - Pipeline by PNP Therapeutics, Inc., H2 2016
Oropharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
Oropharyngeal Cancer - Pipeline by VLPbio, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Oropharyngeal Cancer - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Oropharyngeal Cancer, H2 2016
Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Oropharyngeal Cancer - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 136 pages
Ureter Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 103 pages
Rectal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 112 pages
Thymus Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 109 pages

Ask Your Question

Oropharyngeal Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: